Amgen inks $50M AI drug discovery deal

Amgen, a Thousand Oaks, Calif.-based biopharmaceutical company, will partner with Generate Biomedicines for a research collaboration agreement to discover and create five protein therapeutics for clinical targets.

Amgen will pay $50 million upfront to fund the five programs, with a potential transaction value of $1.9 billion plus future royalties, according to a Jan. 6 press release.

For each program, Amgen will pay up to $370 million in future milestones and royalties. It will also participate in a future financing round for Generate.

Cambridge, Mass.-based Generate Biomedicines is a company that uses machine learning and AI to program protein therapeutics.

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like

 

Featured Whitepapers